Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial

Drayson, MT, Bowcock, S, Planche, T et al. (23 more authors) (2019) Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial. The Lancet Oncology, 20 (12). pp. 1760-1772. ISSN 1470-2045

Abstract

Metadata

Authors/Creators:
Copyright, Publisher and Additional Information: © 2019 The Author(s). Published by Elsevier Ltd. This is an open access article under the terms of the Creative Commons Attribution License (CC-BY 4.0), which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Dates:
  • Published: December 2019
  • Published (online): 23 October 2019
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Leeds Institute of Health Sciences (Leeds) > Academic Unit of Health Economics (Leeds)
Depositing User: Symplectic Publications
Date Deposited: 22 Nov 2019 11:44
Last Modified: 19 Dec 2019 15:15
Status: Published
Publisher: Elsevier
Identification Number: https://doi.org/10.1016/s1470-2045(19)30506-6
Related URLs:

Share / Export

Statistics